文献速递主动脉外科

既往心血管手术后再次全主动脉弓置换术:426例连续患者的结果

Reoperative total arch replacement after previous cardiovascular surgery: Outcomes in 426 consecutive patients.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-08-30

该研究基于单中心主动脉数据库,分析1997年至2022年426例全主动脉弓置换术患者,其中150例(35%)有既往心血管手术史(再次手术组),276例(65%)为首次心血管手术。再次手术组手术死亡率更高(3.3% vs 0.4%,P=.040),主要不良事件风险增加约4倍(95%CI 1.41-11.49,P=.009),10年生存率更低(76% vs 82.2%;HR 1.79;95%CI 1.12-2.86,P=.015)。

要点

  • 再次全主动脉弓置换术占全部全主动脉弓置换术的35%(150/426)。
  • 再次手术组手术死亡率为3.3%,首次手术组为0.4%(P=.040)。
  • 再次手术组主要不良事件风险约为首次手术组的4倍(95%CI 1.41-11.49,P=.009)。

核心结论

  • 再次全主动脉弓置换术技术上具有挑战性,与手术死亡率和不良事件增加相关。
  • 通过细致的手术规划和关注终末器官保护可获得令人满意的结果。
  • 再次全主动脉弓置换术患者晚期再干预率显著更高,未来研究应关注识别可能从更积极的初次手术中获益的高危群体。

研究设计与样本

  • 查询本机构主动脉数据库,纳入1997年至2022年连续接受全主动脉弓置换术的患者。
  • 共426例患者,其中150例(35%)有既往心血管手术史(再次手术组),276例(65%)为首次心血管手术。
  • 比较再次手术组与首次手术组的结果。

主要发现

  • 再次手术组更年轻(61±13岁 vs 71±11岁,P<.001),合并症更多:缺血性心脏病(12% vs 4.3%,P=.006)、既往卒中(36% vs 14.5%,P<.001)、肾功能不全(24% vs 12.7%,P=.004)。
  • 再次手术组心脏缺血时间更长(119.3±45.5分钟 vs 98±31.9分钟,P<.001)。
  • 再次手术组手术死亡率更高(3.3% vs 0.4%,P=.040)。
  • 再次手术组主要不良事件风险增加约4倍(95%CI 1.41-11.49,P=.009)。
  • 再次手术组10年生存率更低(76% vs 82.2%;HR 1.79;95%CI 1.12-2.86,P=.015),晚期再干预需求更高,主要涉及下游主动脉(HR 1.29;95%CI 1.03-1.62,P=.024)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Total aortic arch replacement (TAR) after previous cardiovascular surgery is technically challenging and is becoming more frequent as outcomes for primary arch repair have improved. primary. We analyzed outcomes of reoperative compared with first-time TAR. METHODS: The institutional aortic database was queried to identify consecutive patients undergoing TAR between 1997 and 2022. In total, 426 patients underwent TAR, of whom 150 (35%) had previous cardiovascular surgery (reop TAR) and 276 (65%) underwent their first cardiovascular operation. RESULTS: The reop TAR group was younger (61 ± 13 vs 71 ± 11, P < .001) with more comorbidities such as ischemic heart disease (12% vs 4.3%, P = .006), previous stroke (36% vs 14.5%, P < .001), and renal impairment (24% vs 12.7%, P = .004). Reop TAR had longer cardiac ischemic times (119.3 ± 45.5 minutes vs 98 ± 31.9 minutes, P < .001), a greater operative mortality (3.3% vs 0.4%, P = .040), and incurred a 4-fold increased risk of major adverse event (95% confidence interval [CI], 1.41-11.49, P = .009). Ten-year survival was also lower in the reop TAR cohort (76% vs 82.2%; hazard ratio, 1.79; 95% CI, 1.12-2.86, P = .015) and there was greater need for late reinterventions, mainly on the downstream aorta (hazard ratio, 1.29; 95% CI, 1.03-1.62, P = .024). CONCLUSIONS: Reop TAR is a technically challenging operation and is associated with increased operative mortality and adverse events. Gratifying results can be obtained with meticulous surgical planning and focused attention on end-organ protection. Late reinterventions occur in a significantly greater percentage of patients undergoing reop TAR, and future studies should focus attention on identifying those at-risk groups who may benefit from a more aggressive index procedure.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Ram E, Lau C, Dimagli A, et al. Reoperative total arch replacement after previous cardiovascular surgery: Outcomes in 426 consecutive patients. J Thorac Cardiovasc Surg. 2023. PMID: 37657714. doi:10.1016/j.jtcvs.2023.08.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。